Ranibizumab Struktur

Ranibizumab

Bezeichnung:Ranibizumab

CAS-Nr347396-82-1

Englisch Name:Ranibizumab

CBNumberCB12495883

SummenformelC11H12N2O2

Molgewicht204.22518

MOL-Datei347396-82-1.mol

Ranibizumab physikalisch-chemischer Eigenschaften

Aggregatzustand	Liquid
Farbe	Colorless to light yellow
CAS Datenbank	347396-82-1

Ranibizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Ranibizumab is a recombinant, humanized, IgG1 monoclonal antibody fragment (Fab) that neutralizes all active forms of vascular endothelial growth factor A (VEGF-A), and it is indicated for the treatment of neovascular age-related macular degeneration (AMD). It consists of a nonbinding human sequence and a high-affinity binding epitope (Fab fragment) derived from the mouse. The full-length RhuMab VEGF (bevacizumab) was launched previously by Genentech for the treatment of colorectal cancer. Both the antibody fragment and the full-length antibody bind to and inhibit all active forms of VEGF-A and are derived from the same mouse monoclonal antibody. However, ranibizumab has been genetically engineered through a process of selective mutation to increase its affinity for binding and inhibiting the growth factor.
Originator
Genentech (US)
Verwenden
Ranibizumab, a humanized antigen binding portion of a murine anti- VEGF monoclonal antibody with a mature high affinity for all VEGF isoforms, has been approved as an intravitreal treatment for neovascular AMD and is the first such treatment to improve visual acuity (VA) in neovascular AMD.
CRUISE is multicenter, randomized, double-masked, sham injectioncontrolled Phase III study of 392 participants designed to assess the efficiency and safety profile of ranimizumab for macular edema associated to CRVO. The month 6 result showed that 46.2% (61/132) of patients received 0.3 mg of ranimizumab and 47.7% (62/130) received 0.5 mg of ranimizumab had their vision improved by 15 letters or more compared to 16.9% (22/130) of patients receiving sham injections and mean gain was observed beginning at day seven with an 8.8 and 9.3 letter gain in the 0.3 mg and 0.5 mg study arms of ranimizumab, respectively, compared with 1.1 letters in the sham injection arm.
Verwenden
antiangiogenic monoclonal antibody macular degeneration therapy
Trademarks
Lucentis

Ranibizumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

347396-82-1, Ranibizumab Verwandte Suche:

Send Inquriy